Cardiac Amyloidosis Market
Report ID: SQMIG35I3385
Report ID: SQMIG35I3385
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I3385 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
176
|Figures:
79
Global Cardiac Amyloidosis Market size was valued at USD 2.85 Billion in 2024 and is poised to grow from USD 3.1 Billion in 2025 to USD 6.14 Billion by 2033, growing at a CAGR of 8.9% during the forecast period (2026-2033).
Reimbursement frameworks are a decisive factor shaping cardiac amyloidosis market because favorable coverage boosts patient access and revenue. In United States, Medicare’s inclusion of tafamidis under Part D set a template that European systems followed, prompting insurers in Germany and United Kingdom to negotiate agreements that limit budget impact while expanding formularies.
This environment encourages biotech firms to develop RNA‑based silencers, illustrated by Phase III trial of vutrisiran aimed at lowering transthyretin production via infusions. As a result, pipeline broadens options for patients intolerant to drugs and creates demand for diagnostic imaging and biomarker services, reinforcing a cycle of growth and innovation.
How is AI-driven diagnostics influencing the global cardiac amyloidosis market growth?
AI driven diagnostics are reshaping the cardiac amyloidosis industry by enabling earlier and more accurate identification of the disease. Advanced imaging algorithms can highlight subtle patterns of amyloid deposition that traditional methods often miss, allowing clinicians to intervene before irreversible damage occurs. Integration of AI tools with electronic health records streamlines patient pathways, reducing diagnostic delays and improving referral efficiency. These capabilities also expand the pool of eligible patients for emerging therapies, encouraging pharmaceutical investment and accelerating clinical trial enrollment. As physicians gain confidence in AI assisted assessments, adoption spreads across hospitals and specialty centers, driving overall market expansion and fostering a more proactive care model.
Siemens Healthineers in March 2024, introduced an AI powered cardiac MRI solution that enhances detection of amyloid infiltration, shortening diagnostic timelines and supporting broader market growth through improved clinical confidence.
Market snapshot - (2026-2033)
Global Market Size
USD 2.85 Billion
Largest Segment
Imaging
Fastest Growth
Biomarker Testing
Growth Rate
8.9% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global cardiac amyloidosis market is segmented by diagnosis, disease type, treatment, route of administration, end user, distribution channel and region. Based on diagnosis, the market is segmented into Imaging, Biomarker Testing, Biopsy & Histopathology, Genetic Testing and Others. Based on disease type, the market is segmented into Transthyretin Amyloidosis (ATTR) and Light Chain Amyloidosis (AL). Based on treatment, the market is segmented into Transthyretin Stabilizers, Gene Silencing Therapies, Chemotherapy, Monoclonal Antibodies, Supportive Care and Others. Based on route of administration, the market is segmented into Oral, Intravenous and Subcutaneous. Based on end user, the market is segmented into Hospitals, Specialty Cardiology Clinics, Ambulatory Surgical Centers and Diagnostic Centers. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Imaging segment dominates because it provides the most immediate visualization of amyloid deposits, enabling clinicians to assess cardiac involvement quickly. Its non invasive nature, coupled with advanced modalities such as cardiac MRI and scintigraphy, builds confidence in diagnosis and guides therapeutic decisions. Clinicians favor imaging due to its reproducibility, broad availability across care settings, and ability to monitor disease progression over time for both early detection and longitudinal management across diverse patient populations in real world settings.
However, biomarker testing segment emerges as the most rapidly expanding segment because blood based assays detect misfolded proteins with sensitivity, reducing reliance on invasive procedures. Evidence supports its role in screening and risk stratification, prompting adoption in cardiology workflows. This acceleration fuels market entry of diagnostic kits and creates revenue streams for manufacturers.
Transthyretin stabilizers segment dominates with large cardiac amyloidosis market share because it directly prevents amyloid fibril formation by binding to the transthyretin tetramer, stabilizing its native structure. This mechanism addresses the root cause of ATTR cardiac amyloidosis, offering clinicians a targeted oral therapy with established safety profile. Clinicians and patients prefer this approach due to ease of administration, predictable pharmacodynamics, and demonstrated efficacy in slowing disease progression, reinforcing its market leadership across diverse patient populations in real world settings.
As per cardiac amyloidosis market outlook, gene silencing therapies segment emerges as the most rapidly expanding segment because RNA based interventions suppress transthyretin production at the hepatic level. Regulatory approvals and clinical evidence boost physician confidence, driving uptake in centers. This momentum creates market opportunities, fuels investment in delivery platforms, and widens therapeutic options for patients with few alternatives.
To get detailed segments analysis, Request a Free Sample Report
The dominance of North America drives from a highly coordinated ecosystem that blends advanced clinical research infrastructure with robust reimbursement frameworks and a strong emphasis on early diagnosis. Leading academic centers and specialty clinics drive innovative therapeutic adoption, while well‑established payer models facilitate patient access to emerging treatments. A culture of collaboration between biotech firms, regulatory bodies, and patient advocacy groups accelerates the translation of scientific breakthroughs into clinical practice. Additionally, extensive physician awareness programs and comprehensive disease‑management guidelines create a supportive environment for sustained market leadership. The convergence of these factors positions the region as a benchmark for therapeutic innovation, patient outcomes, and market fluidity in the cardiac amyloidosis space.
As per cardiac amyloidosis market regional outlook, United States benefits from a mature network of specialized heart centers that integrate cutting‑edge imaging and genetic testing into routine care. Strong collaboration between pharmaceutical innovators and research hospitals accelerates clinical trial enrollment and regulatory pathways. Reimbursement structures emphasize value‑based care, encouraging adoption of newer therapeutic options. Patient advocacy groups actively promote disease awareness, supporting earlier detection and treatment adherence. This combination of research depth, payer support, and stakeholder engagement sustains a high‑growth environment for cardiac amyloidosis solutions.
As per cardiac amyloidosis market regional forecast, Canada is reinforced by a publicly funded health system that prioritizes equitable access to advanced diagnostics and therapies. Provincial health authorities work closely with clinical experts to incorporate emerging treatment protocols into standard care pathways. Academic institutions play a pivotal role in generating real‑world evidence that informs guideline updates. Collaborative frameworks between biotech firms and research hospitals facilitate swift integration of novel agents. Patient organizations contribute to education campaigns, enhancing early identification and fostering a supportive environment for therapeutic uptake.
Europe’s rapid expansion is propelled by a harmonized regulatory landscape that streamlines multi‑country approvals and encourages cross‑border clinical collaborations. Strong national health services invest heavily in specialized cardiac care networks, fostering widespread adoption of precision diagnostics. Academic excellence across key markets fuels continuous research output, while public‑private partnerships accelerate the introduction of innovative therapies. Growing clinician expertise and targeted educational initiatives raise disease awareness, prompting earlier referrals and treatment initiation. The region’s emphasis on cost‑effective care models and outcome‑focused reimbursement further supports market growth, positioning Europe as a dynamic hub for cardiac amyloidosis advancement.
Germany is anchored by a dense network of tertiary hospitals and research institutes that lead in diagnostic imaging and biomarker development. The German healthcare system’s structured reimbursement pathways enable swift incorporation of new treatment modalities. Close collaboration between industry and academic centers drives robust clinical trial activity, generating high‑quality evidence that informs national guidelines. Professional societies actively disseminate best‑practice recommendations, fostering consistent clinical adoption across the country.
United Kingdom benefits from a national health service that prioritizes equitable access to innovative therapies through centralized funding mechanisms. Leading cardiac centers integrate advanced imaging techniques with multidisciplinary care pathways, accelerating diagnosis and management. Ongoing partnerships between biotech firms and university hospitals support rapid trial enrollment and real‑world evidence generation. Patient advocacy groups drive public awareness campaigns that enhance early detection and promote adherence to treatment protocols.
France is emerging under a health framework that emphasizes specialized care pathways and collaborative research networks. Regional hospitals increasingly adopt state‑of‑the‑art diagnostic tools, supported by national guidelines that encourage early intervention. Academic collaborations with pharmaceutical developers facilitate the evaluation of novel agents within the French clinical setting. Patient support organizations play a vital role in raising disease visibility, contributing to a growing awareness that underpins market momentum.
Asia Pacific is strengthening its position through strategic investments in healthcare infrastructure and a concerted focus on expanding specialist capabilities. Countries are prioritizing the development of dedicated cardiac centers equipped with advanced imaging and laboratory facilities, enabling more accurate disease identification. Collaborative initiatives between regional pharmaceutical companies and global research institutions foster knowledge transfer and accelerate clinical trial participation. Growing physician education programs raise expertise in managing complex cardiac conditions, while government health agendas increasingly recognize the importance of rare disease frameworks. Together, these elements are cultivating a fertile environment for the introduction and adoption of innovative cardiac amyloidosis therapies across the region.
Japan is supported by a sophisticated healthcare system that integrates cutting‑edge imaging technologies within tertiary hospitals. Strong ties between industry and leading academic centers promote rapid clinical evaluation of new therapies. Government health policies encourage reimbursement for advanced treatments that demonstrate clinical benefit, facilitating broader patient access. Patient advocacy networks actively disseminate educational resources, fostering greater disease awareness and earlier diagnostic referrals.
South Korea benefits from a rapidly evolving medical landscape that emphasizes precision medicine and specialized cardiac care. Major university hospitals are adopting comprehensive diagnostic algorithms that combine imaging and biomarker analysis. Collaborative research programs with multinational partners accelerate clinical trial enrollment and data generation. National health insurance schemes increasingly provide coverage for innovative therapeutic options, supporting timely patient access and reinforcing market growth.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Diagnostic Awareness
Advancements in Targeted Therapies
High Treatment Cost Burden
Limited Access to Specialized Centers
Request Free Customization of this report to help us to meet your business objectives.
The global cardiac amyloidosis industry is highly competitive, with pharmaceutical and biotechnology companies focusing on developing disease-modifying therapies, expanding clinical trial pipelines, and strengthening their presence in rare cardiovascular disease treatment. Key players such as Pfizer Inc., BridgeBio Pharma, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, Novo Nordisk, Johnson & Johnson, Alexion Pharmaceuticals, Intellia Therapeutics, Silence Therapeutics, Prothena Corporation, and Sobi are actively involved in advancing treatments for transthyretin amyloid cardiomyopathy (ATTR-CM) and related amyloid disorders.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis the global cardiac amyloidosis market growth is expanding rapidly driven primarily by increasing diagnostic awareness that is pushing earlier patient identification and fueling demand for imaging tools the segment that currently dominates the diagnostic landscape. A second driver is the surge in targeted therapies especially transthyretin stabilizers and gene‑silencing agents which are attracting investment and accelerating clinical adoption. However high treatment cost burden restrains broader uptake by limiting reimbursement and patient access. North America leads the market benefitting from robust research infrastructure favorable payer models and widespread specialist networks that reinforce its dominance and positions it as the benchmark for future growth worldwide. The global cardiac amyloidosis market trend is witnessing significant growth, driven by increasing disease awareness, improved diagnostic capabilities, and the introduction of advanced targeted therapies.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 2.85 Billion |
| Market size value in 2033 | USD 2.99 Billion |
| Growth Rate | 8.9% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Cardiac Amyloidosis Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Cardiac Amyloidosis Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Cardiac Amyloidosis Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Cardiac Amyloidosis Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Cardiac Amyloidosis Market size was valued at USD 2.85 Billion in 2024 and is poised to grow from USD 3.1 Billion in 2025 to USD 2.99 Billion by 2033, growing at a CAGR of 8.9% during the forecast period (2026-2033).
Top Player’s Company Profile 'Pfizer Inc', 'Alnylam Pharmaceuticals Inc', 'Ionnis Pharmaceuticals Inc', 'Ionis Pharmaceuticals Inc', 'BridgeBio Pharma Inc', 'Eidos Therapeutics Inc', 'Intellia Therapeutics Inc', 'Prothena Corporation plc', 'Alexion Pharmaceuticals Inc', 'AstraZeneca plc', 'GlaxoSmithKline plc', 'Sanofi SA', 'Novartis AG', 'Takeda Pharmaceutical Company Limited', 'Johnson & Johnson Services Inc', 'Merck & Co Inc', 'Bristol Myers Squibb Company', 'Amgen Inc', 'Neurimmune AG', 'AC Immune SA'
Improved physician education and broader screening initiatives are expanding recognition of cardiac amyloidosis symptoms, leading to earlier patient identification. As clinicians become more adept at distinguishing the disease from other cardiomyopathies, referral pathways to appropriate treatment centers are strengthening. This heightened awareness drives demand for diagnostic tools and therapeutic options, encouraging pharmaceutical investment and supporting market expansion. Consequently, a larger patient pool enters clinical management, sustaining revenue streams and prompting further research into disease-modifying interventions. These developments also foster collaborative networks that streamline clinical trial enrollment, further accelerating therapeutic availability.
Precision Diagnostics Expansion: Advancements in molecular imaging and biomarker profiling are enabling earlier and more accurate identification of cardiac amyloidosis subtypes, driving clinicians toward personalized treatment pathways. The integration of artificial intelligence algorithms with imaging data enhances pattern recognition, reducing diagnostic uncertainty. As healthcare providers prioritize timely intervention, demand rises for diagnostic platforms, prompting manufacturers to invest in collaborations and approvals. This shift not only improves patient outcomes but also creates revenue streams for technology firms and expands market adoption across care settings.
Why does North America Dominate the Global Cardiac Amyloidosis Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
